Calydon Capital Dumps $9 Million of ZoomInfo Amid Stock's 92% Decline Since 2021

Calydon Capital sold 892,298 ZoomInfo shares in Q4 2025 — an estimated $9.19M trade — leaving 84,210 shares valued at $856,416 (0.14% of the fund's 13F AUM, down from 1.7%). ZoomInfo was trading at $5.93 on 2026-03-19 (down ~43.5% Y/Y and ~92% since 2021); company TTM revenue $1.25B, net income $124.2M and FCF ~$455M with an EV/FCF near 12. The trade is unlikely to move the market materially given ZoomInfo's $1.81B market cap, but the near-complete exit by a long-term holder underscores investor caution amid stalled sales growth and competitive pressures.

Analysis

Calydon’s near-complete exit is a classic institutional signal: when a long-term fundamental holder de-risks into passive ETFs, the immediate effect is not just a share sale but a structural reduction in the universe of likely buyers. That amplifies downside risk from flow dynamics — thin institutional interest plus retail fatigue makes short-term liquidity events (earnings, guide tweaks, or negative headlines) more damaging than they would be for a name with steady active ownership.

On fundamentals, ZoomInfo sits at an awkward inflection where robust cash generation coexists with a stalled top-line narrative; this makes the name highly sensitive to multiple compression/expansion driven by product-led AI adoption rather than raw revenue beats. The second-order winner from this reset will be players that embed go-to-market data into platform lock‑ins (CRMs, CDPs, and large enterprise suites): they enjoy stickiness that pure data providers lack and can monetize AI features at higher ARPU.

Key catalysts to watch are adoption velocity of AI-enabled workflows and any evidence of sustained ARPA expansion among large customers — these are 3–12 month events capable of re-pricing the equity. Tail risks include rapid commoditization of contact/data layers by open LLMs or regulatory shocks to data collection practices; those are multi-quarter to multi-year drags that could keep multiples depressed even with stable cash flow.

From a portfolio construction view, this is a classic value-vs-growth arbitrage: you can buy the optionality of a re-rate cheaply but must size and hedge for a binary outcome. The preferred play is a structured, hedged position that monetizes a potential multiple recovery while capping downside from another round of de-rating or data/regulatory setbacks.

Key Decisions for Investors

• Long GTM (small starter position 2–3% NAV) with a 12‑18 month horizon; tranche in three equal parts over 3 months. Hedge with 0.5–1.0x notional of 6‑9 month protective puts (Otm) to cap downside; target asymmetric payoff: 40–80% upside on a multiple re-rate vs max 25–35% downside (net of hedge) if growth stalls.
• Pair trade: Long NVDA (1.0x) / Short GTM (1.0x) for 6–18 months to express AI-driven platform winners vs legacy data distributors. This reduces macro beta while capturing reallocation from data vendors into infrastructure/AI plays — expect NVDA to outperform materially if AI capex accelerates; cap position size to limit event risk on NVDA earnings.
• Options alternative: Buy a 12‑month GTM call spread (debit-limited) sized to 1–2% NAV to buy optionality cheaply. Sell nearer-term calls (covered) if you take an outright long to offset carry, converting an equity stake into a collar if you prefer capped upside for premium income.
• Risk monitor & trigger: if two consecutive quarters show declining net retention or a material slowdown in large-customer expansion, cut exposure to zero within 30 days. Conversely, if management posts clear product-led AI ARPA lift across two quarters, add to the long at the first quarterly report to capture re-rate momentum.